CEO Giroir announces Altesa’s IND for vapendavir has the FDA green light for clinical study at AdvanSE Conference ATLANTA – May 26, 2022 – Altesa BioSciences, Inc. (Altesa), a clinical-stage biopharmaceutical company developing and commercializing novel antiviral...
George Painter, Emory Professor and CEO of DRIVE, awarded $52 million to co-lead Antiviral Countermeasures Development Center ATLANTA, May 25, 2022 – Altesa BioSciences, Inc., a clinical-stage biopharmaceutical company developing and commercializing novel antiviral...
Recent Comments